Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
A549 Cells
CD4-Positive T-Lymphocytes
/ immunology
Carcinoma, Non-Small-Cell Lung
/ immunology
Case-Control Studies
Flow Cytometry
Forkhead Transcription Factors
/ biosynthesis
Humans
Immunohistochemistry
Interleukin-12 Subunit p35
/ biosynthesis
Interleukins
/ biosynthesis
Lung
/ immunology
Lung Neoplasms
/ immunology
Minor Histocompatibility Antigens
/ biosynthesis
RNA, Messenger
/ genetics
T-Lymphocytes, Regulatory
/ immunology
Tumor Escape
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
30
08
2018
accepted:
15
03
2019
revised:
08
02
2019
pubmed:
9
4
2019
medline:
29
2
2020
entrez:
9
4
2019
Statut:
ppublish
Résumé
The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease. Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Immunohistochemistry, FACS analysis, real-time PCR, as well as western blot from samples of the control (CTR), peri-tumoural (PT) and the tumoural (TU) region of the lung derived from patients with NSCLC and 10 controls were performed. Here we found elevated levels of IL-35 in the TU region as well as postoperative serum from patients with lung adenocarcinoma. Consistently, we found an increased expression of IL-35 Induced IL-35
Sections du résumé
BACKGROUND
The immunosuppressive role of the cytokine IL-35 in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, we analysed the localisation and regulation of IL-35 in the lung of patients with non-small cell lung cancer (NSCLC) to further elucidate the immune-escape of cancer cells in perioperative course of disease.
METHODS
Interleukin 35 (IL-35) was measured by ELISA in postoperative serum from 7 patients with NSCLC as well as 8 samples from healthy controls. Immunohistochemistry, FACS analysis, real-time PCR, as well as western blot from samples of the control (CTR), peri-tumoural (PT) and the tumoural (TU) region of the lung derived from patients with NSCLC and 10 controls were performed.
RESULTS
Here we found elevated levels of IL-35 in the TU region as well as postoperative serum from patients with lung adenocarcinoma. Consistently, we found an increased expression of IL-35
CONCLUSIONS
Induced IL-35
Identifiants
pubmed: 30956278
doi: 10.1038/s41416-019-0444-3
pii: 10.1038/s41416-019-0444-3
pmc: PMC6734661
doi:
Substances chimiques
EBI3 protein, human
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
IL12A protein, human
0
Interleukin-12 Subunit p35
0
Interleukins
0
Minor Histocompatibility Antigens
0
RNA, Messenger
0
interleukin-35, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-912Références
Immunity. 2002 Jun;16(6):779-90
pubmed: 12121660
Immunity. 2003 Nov;19(5):641-4
pubmed: 14614851
Immunol Rev. 2008 Dec;226:248-62
pubmed: 19161429
Nat Rev Clin Oncol. 2011 Nov 08;8(12):691
pubmed: 22064462
Nat Immunol. 2010 Dec;11(12):1093-101
pubmed: 20953201
Cancer Res. 2018 Jul 1;78(13):3619-3633
pubmed: 29691251
Adv Exp Med Biol. 2016;941:213-225
pubmed: 27734415
Oncoimmunology. 2016 Dec 14;6(1):e1256526
pubmed: 28197372
Br J Cancer. 2016 Oct 25;115(9):e11
pubmed: 27657338
J Exp Clin Cancer Res. 2013 Nov 25;32:97
pubmed: 24274066
Ann Oncol. 2011 Mar;22(3):575-581
pubmed: 20801905
Nat Immunol. 2012 Jul 19;13(8):722-8
pubmed: 22814351
Clin Exp Immunol. 2015 Aug;181(2):253-66
pubmed: 25845911
Ann Oncol. 2018 Apr 1;29(4):1078
pubmed: 29267838
J Thorac Oncol. 2017 Mar;12(3):585-590
pubmed: 27639677
J Cancer Res Clin Oncol. 2018 Oct;144(10):2059-2066
pubmed: 30062488
Neoplasma. 2017;64(2):253-261
pubmed: 28043153
Immunity. 2016 Feb 16;44(2):316-29
pubmed: 26872697
Lupus. 2015 Oct;24(12):1257-66
pubmed: 25966926
Cancer Treat Rev. 2018 Mar;64:21-29
pubmed: 29454155
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
J Dig Dis. 2015 Jan;16(1):1-6
pubmed: 25476593
Lancet Oncol. 2016 May;17(5):541-3
pubmed: 27301025
Nat Commun. 2017 Sep 28;8(1):719
pubmed: 28959012
Cancer Res. 2017 Nov 1;77(21):5963-5976
pubmed: 28883000
Br J Cancer. 2017 Nov 21;117(11):1644-1655
pubmed: 29016555
Ann N Y Acad Sci. 2010 Jan;1183:123-48
pubmed: 20146712
Oncol Rep. 2012 Aug;28(2):615-21
pubmed: 22614805
Oncoimmunology. 2018 Apr 25;7(8):e1456612
pubmed: 30221050
Curr Mol Med. 2017;17(8):527-540
pubmed: 29473504
J Immunol. 2011 Jun 15;186(12):6661-6
pubmed: 21576509
Br J Cancer. 2018 Jan;118(1):38-42
pubmed: 29149104
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Eur J Immunol. 2015 Jun;45(6):1736-47
pubmed: 25820702
Cancer. 2012 Jun 1;118(11):2889-99
pubmed: 22020674
Nature. 2007 Nov 22;450(7169):566-9
pubmed: 18033300